Wendy Saffell-Clemmer, Lead Scientist, R&D, Senior Director Baxter Pharmaceuticals & Baxter Biopharma Solutions05.07.19
The number of seasonal influenza vaccine doses in the U.S. has increased 10-fold since 1980 (Table 1) with 169.1 million doses distributed in the U.S. during the 2018-2019 season.1 The development of seasonal influenza vaccines is a carefully choreographed effort beginning with a meeting by an FDA advisory committee in March2 to decide which strains to include in the next season’s vaccine, followed by production of potency standards—in parallel with manufacturers’ preparations—for the new campaign. Seasonal influenza vaccines are unique as their limited time span from strain selection to distribution requires most vaccine producers to rely on outsourcing partners to mitigate risk and ensure timely production. Demand for contract manufacturing organizations (CMOs) support for seasonal influenza vaccines is expected to increase as the seasonal influenza vaccine market is projected to reach more than $4 billion by the end of 2022.3
While many CMOs claim vaccine fill-finish experience,4 seasonal campaigns present logistical challenges that few outsourcing partners are prepared to accom
While many CMOs claim vaccine fill-finish experience,4 seasonal campaigns present logistical challenges that few outsourcing partners are prepared to accom
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
